Wegovy-maker Novo Nordisk ousted CEO Lars Fruergaard Jorgensen on Friday over concerns the company is losing its first-mover ...

Activist hedge fund Parvus Asset Management is building a stake in Novo Nordisk, after the company lost its first mover ...

U.S.-listed shares of Novo Nordisk declined in the opening minutes of trading Friday on the surprise news that CEO Lars Fruergaard Jørgensen is stepping down from the Danish drugmaker.

Novo Nordisk's Q1 showed robust sales/EPS growth, fueled by soaring GLP-1 demand in a multi-billion dollar market. Read why I ...

Detailed price information for Novo Nordisk A/S ADR (NVO-N) from The Globe and Mail including charting and trades.

Novo Nordisk (NYSE:NVO) rose to its highest level in over two months Monday after a media report said hedge fund Parvus Asset ...

Novo Nordisk’s stock has tumbled over 50% since its peak around a year ago, and it just ousted its CEO. Former employees say ...

In an effort to maximize the earnings potential of its plaque psoriasis cream, Danish dermatology biotech MC2 Therapeutics has hired a former GLP-1 leader to steer the ship. Trine Ahlgreen is the new ...

Novo Nordisk's popular weight-loss and diabetes drugs Wegovy and Ozempic may in very rare cases cause a serious eye condition ...

I've been a Novo Nordisk bull for quite some time now, and I wouldn't be as spooked by the situation. Here's why. Novo Nordisk got a two-year-plus head start in the white-hot obesity drugs market, ...